Levatinib mesylate is a synthetic oral vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase inhibitor with potential anti-tumor activity. E7080 blocks the activation of VEGFR2 through VEGF, thereby inhibiting the VEGF receptor signaling pathway, reducing the migration and proliferation of endothelial cells, as well as endothelial cell apoptosis.